AN2 Therapeutics, Inc. (ANTX)

NASDAQ: ANTX · IEX Real-Time Price · USD
10.50
+0.31 (3.04%)
Aug 8, 2022 4:00 PM EDT - Market closed

Income Statement (Quarterly)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Quarter Ended 2022-03-312021-12-312021-03-31
Selling, General & Admin
2.05-0.4
Research & Development
5.63-1.65
Operating Expenses
7.68-2.05
Operating Income
-7.68--2.05
Other Expense / Income
-0.030-0
Pretax Income
-7.660-2.05
Net Income
-7.66--2.05
Preferred Dividends
1.82-0.76
Net Income Common
-9.48--2.81
Shares Outstanding (Basic)
333
Shares Outstanding (Diluted)
3-3
EPS (Basic)
-2.98--1.07
EPS (Diluted)
-2.98--1.07
Free Cash Flow Per Share
-2.12--0.59
EBITDA
-7.64--2.05
Depreciation & Amortization
0.02-0
EBIT
-7.66--2.05
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).